Sunday 18 October 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024. In the quarter to June 2026, revenue grew 14,590.2%, EPS fell 72.4% and free cash flow fell 56.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.83
0.03
+1.07%
Follow EVAX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
(4.54) | (16.30) | (16.65) | — | — | — | — | — | — |
P/S ratio |
2.84 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(10.33) | (36.69) | (38.52) | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Beneish M-Score |
(2.17) | 37.74 | — | — | — | — | — | — | — |
P/Operating CF |
(3.93) | (0.52) | (19.45) | — | — | — | — | — | — |
P/B ratio |
1.78 | 0.00 | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
1.79 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Sales |
1.33 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
(0.47) | (0.32) | (3.68) | — | — | — | — | — | — |
EV/FCF |
(0.47) | (0.32) | (3.61) | — | — | — | — | — | — |
Quick Ratio |
5.66 | 1.72 | 0.90 | 3.77 | 7.76 | 1.56 | 6.03 | 0.87 | — |
Current Ratio |
5.85 | 2.01 | 1.18 | 4.51 | 8.03 | 2.22 | 6.36 | 0.89 | — |
Net Debt/EBITDA |
1.87 | (0.27) | (0.23) | 0.13 | 1.11 | 0.35 | 0.88 | (0.20) | — |
Debt/Assets |
25.15% | 78.39% | 81.81% | 45.19% | 8.41% | 0.17% | 0.32% | 101.82% | 0.00% |
Debt/Equity |
0.42 | (5.92) | (2.23) | 1.20 | 0.10 | 0.00 | 0.00 | (9.31) | — |
Asset Turnover |
0.37 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.86 | 1.22 | 0.80 | 1.11 | 0.89 | 0.83 | 0.63 | 0.36 | — |
Capex/Depreciation |
(0.02) | 0.00 | (0.14) | (0.51) | (3.96) | (1.75) | (0.75) | 0.00 | — |
Interest Coverage |
(2.31) | (4.72) | (13.20) | (16.75) | (28.23) | (74.30) | (8.89) | (777.62) | — |
| (100.18%) | 331.20% | (1,238.11%) | (113.74%) | (124.29%) | (183.15%) | (265.57%) | (131.17%) | — | |
| (37.69%) | (83.29%) | (126.74%) | (74.51%) | (94.12%) | (130.31%) | (114.25%) | (129.91%) | — | |
ROIC |
(608.14%) | (421.78%) | (5,979.80%) | (311.38%) | (442.73%) | (846.00%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(32.16%) | (133.57%) | (394.46%) | (129.45%) | (69.00%) | (240.52%) | (119.90%) | 609.59% | — |
Average Days of Receivables |
41.99 | 168.09 | 4,075.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
132.51% | 312.71% | 16,323.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
90.16% | 227.84% | 14,183.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
4.08% | 10.68% | 656.16% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.45 | (1.75) | (0.09) | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(43.42%) | (232.17%) | (35.97%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(100.88%) | (577.57%) | (29.03%) | — | — | — | — | — | — |
Revenue per Share |
1.17 | 3.12 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.03) | (12.06) | (32.36) | (54.51) | (56.25) | (40.29) | (25.27) | (0.14) | — |
Capex per Share |
0.00 | 0.00 | (0.16) | (0.62) | (3.49) | (0.60) | (0.22) | 0.00 | — |
Free Cash Flow per Share |
(1.04) | (12.06) | (32.52) | (55.13) | (59.74) | (40.89) | (25.49) | (0.14) | — |
Cash per Share |
3.63 | 5.55 | 10.21 | 27.88 | 82.50 | 18.90 | 34.41 | 0.53 | — |
Shareholders Equity per Share |
2.66 | (1.54) | (8.65) | 17.56 | 83.19 | 22.80 | 33.70 | (0.07) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.66 | (1.54) | (8.65) | 17.56 | 83.19 | 22.80 | 33.70 | (0.07) | — |
Free Cash Flow |
(6.64) | (12.94) | (17.78) | (26.07) | (23.29) | (12.62) | (7.08) | (1.98) | — |
Working Capital |
20.64 | 4.40 | 1.27 | 13.22 | 30.38 | 6.02 | 9.24 | (1.04) | — |
Capital Expenditures |
(0.01) | — | (0.09) | (0.29) | (1.36) | (0.18) | (0.06) | (0.01) | — |
Net Current Asset Value |
13.53 | (5.37) | (9.27) | 3.26 | 26.98 | 6.02 | 9.24 | (1.06) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 1.19 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.19 | 0.17 | 0.14 | 0.12 | 0.07 | 0.48 | 0.80 | 0.57 | — |
Cash ROIC |
(13.99%) | (91.86%) | (155.97%) | (82.91%) | (34.26%) | (97.91%) | (37.35%) | (13.03%) | — |
Accounts Receivable Turnover |
6.26 | 2.84 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,659.54 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.20 | 1.18 | 0.91 | 1.21 | 1.62 | 1.33 | 0.80 | 0.85 | — |
Average Payables |
2.58 | 2.83 | 2.39 | 2.47 | 3.26 | 2.16 | 0.49 | 0.79 | — |
Average Assets |
20.45 | 12.69 | 17.46 | 31.09 | 26.06 | 11.52 | 9.80 | 4.26 | — |
Average Common Equity |
7.69 | (3.19) | 1.79 | 20.37 | 19.74 | 8.20 | 4.22 | 4.22 | — |
Columns are period end dates